Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
Ceryvyn Therapeutics's cash receipts from operating activities for the
six
months ended in Jun. 2025 was $0.01 Mil.
2. Cash Payments:
It represents cash flow paid from operating activities in the direct cash flow method.
Ceryvyn Therapeutics's cash payments for the
six
months ended in Jun. 2025 was $-88.00 Mil.
3. Dividends Paid:
It represents dividend paid to the investors in the direct cash flow method.
Ceryvyn Therapeutics's cash payments for the
six
months ended in Jun. 2025 was $0.00 Mil.
4. Dividends Received:
It represents dividend received on the investment in the direct cash flow method.
Ceryvyn Therapeutics's cash payments for the
six
months ended in Jun. 2025 was $0.00 Mil.
5. Interest Paid:
It represents interest paid on loans, debt or borrowings, in the direct cash flow method.
Ceryvyn Therapeutics's cash payments for the
six
months ended in Jun. 2025 was $-0.01 Mil.
6. Interest Received:
It represents interest received by the company in the direct cash flow method.
Ceryvyn Therapeutics's cash payments for the
six
months ended in Jun. 2025 was $1.91 Mil.
7. Taxes Refund Paid:
It represents tax paid or refund related to operating activities in the direct cash flow method.
Ceryvyn Therapeutics's cash payments for the
six
months ended in Jun. 2025 was $-0.22 Mil.
8. Cash Flow from Others:
These are cash differences caused by the change of cash receipts and cash payments. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its cash position will grow more slowly (or even shrink).
Ceryvyn Therapeutics's cash flow from others for the
six
months ended in Jun. 2025 was $0.22 Mil.
Ceryvyn Therapeutics Cash Flow from Operations Related Terms
Ceryvyn Therapeutics Cash Flow from Operations Historical Data
* Premium members only.
The historical data trend for Ceryvyn Therapeutics's Cash Flow from Operations can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ceryvyn Therapeutics Cash Flow from Operations Chart
Ceryvyn Therapeutics Cash Flow from Operations Calculation
Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.
Ceryvyn Therapeutics's Cash Flow from Operations for the fiscal year that ended in Jun. 2025 is calculated as:
Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-158.64 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Flow from Operations of $-158.64 Mil mean?
Ceryvyn Therapeutics (CKDXF) has a Cash Flow from Operations of $-158.64 Mil as of Jun. 2025. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Ceryvyn Therapeutics and its competitors.
Is Ceryvyn Therapeutics' Cash Flow from Operations too high?
Ceryvyn Therapeutics' current Cash Flow from Operations is $-158.64 Mil.
How does Ceryvyn Therapeutics' Cash Flow from Operations compare to VRTX and REGN?
Ceryvyn Therapeutics' Cash Flow from Operations of $-158.64 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Flow from Operations for a Biotechnology company?
A good Cash Flow from Operations depends on the Biotechnology industry context. However, Cash Flow from Operations should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Flow from Operations mean?
A high Cash Flow from Operations can signal that a stock is expensive relative to its fundamentals. Cash Flow from Operations is the amount of cash earned or paid from standard business operations. View historical data for Ceryvyn Therapeutics and its competitors. Ceryvyn Therapeutics's current Cash Flow from Operations is $-158.64 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (CKDXF) has a current Cash Flow from Operations of $-158.64 Mil. The current Cash Flow from Operations is $-158.64 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Flow from Operations calculated?
Cash Flow from Operations is calculated from a company's financial statements. For Ceryvyn Therapeutics (CKDXF), the current Cash Flow from Operations is $-158.64 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CKDXF has been successfully added to your 
